Effective July 1, 2026,¹ Cigna Healthcare^® will make updates to its U.S. commercial drug formularies to support affordability, clinical appropriateness, and access.

These formulary updates may change how some medications are covered for patients with Cigna Healthcare coverage, and affected patients may need assistance transitioning to covered, clinically appropriate alternative medications.

Key areas of focus

Expanding biosimilar adoption

Cigna Healthcare is expanding its recommendations for certain reference biologics to prioritize the use of the biosimilar option, when clinically appropriate. By preferring certain biosimilars, Cigna Healthcare can drive affordability and potentially lower health care costs.

Promoting lower-cost, clinically appropriate therapies

Cigna Healthcare will remove select high‑cost and multisource brand medications from its formularies to promote lower‑cost, therapeutically equivalent alternatives. In addition, Cigna Healthcare will update quantity limits and prior authorization requirements for select medications.

Additional information

Visit the Cigna for Health Care Professionals website (CignaforHCP.com) to see the complete list of July 1, 2026, changes.

Cigna Healthcare also made updates to prior authorization requirements and expanded access for other select products earlier this year. These changes are also outlined on CignaforHCP.com.

1. For Texas- and Louisiana-insured customers, the effective date may be deferred until the plan renew date, as required by state law.